Introduction
============

Major depressive disorder (MDD) currently affects an estimated 340 million people worldwide.[@B1] In recent years, the point prevalence of MDD among Koreans has been rising in all age groups.[@B2] A 2007 study reported the 12-month prevalence of MDD among Koreans to be 1.7% with a lifetime prevalence of 4.3%, and roughly twice the rate in women.[@B3]

Researchers speculate that the incidence of new cases of depression is currently underestimated,[@B7] where underlying psychological symptoms may be masked by the higher incidence of concomitant painful physical symptoms (PPS), especially in Asian cultures. In these cultures, patients tend to somatize instead of openly expressing their emotional suffering and then seek somatic treatment.[@B8]-[@B11]

Kirmayer[@B12] stated that culture carries great influence on the expression of an individual\'s mental health or illness. Other researchers have also speculated that ethnicity may influence the somatic and psychiatric occurence of depression.[@B13],[@B14] For example, in Korean immigrant culture within the USA, when compared to other cultures, Koreans are less likely to seek medical attention for anxiety, depression or other psychological problems,[@B15] most likely given their strong belief that depression is a normal part of life rather than a mental illness.[@B11],[@B16]

Depression accompanied by painful physical symptoms is also not unfamiliar to Koreans. Although controversial, it has been suggested that a Korean folk syndrome termed \"hwa-byung\", is a culturally patterned way that some Koreans experience depression.[@B17] Hwa-byung is thought to stem from suppressed emotions, manifesting as hostility, a sense of misery, and accompanied by somatic symptoms[@B15],[@B18]-[@B21] such as nonspecific gastrointestinal problems and generalized aches and pains.[@B22] Research from other cultures reports that PPS, including headaches, stomach pain, back pain and vague, poorly localized pain, are reported by up to 76% of all patients with depression.[@B7],[@B23]-[@B25]

High prevalence of PPS in depressed patients has been established in American,[@B24] European,[@B26] and Latin American[@B25] general and psychiatric practice settings, as well as Asian psychiatric settings.[@B27] This paper examines PPS in Korean patients with MDD in psychiatric outpatient settings.

This analysis is part of a larger study covering 6 Asian countries/regions, with the primary objective of evaluating the frequency of PPS in Asian patients treated for an acute MDD episode in a naturalistic clinical practice setting. Here we report the frequency of PPS in the Korean subpopulation and provide clinical information from a Korean perspective, describing the changes in disease severity, treatment patterns, and quality of life observed during the 3-month observational period. We then compare participant outcomes based on the presence (PPS+) or absence (PPS-) of painful physical symptoms.

Methods
=======

Patients
--------

Female and male psychiatric inpatients or outpatients who were older than 18 years of age, with a primary diagnosis of MDD \[Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision (DSM-IV-TR)[@B28] or the International Classification of Diseases, Tenth Revision (ICD-10)[@B29]\], Clinical Global Impressions of Severity (CGI-S) Scale ≥430 and who agreed to receive antidepressant treatment, were enrolled at the discretion of their treating psychiatrist. Patients were enrolled from 7 medical centers including 6 university hospitals throughout Korea.

Patients were not eligible for enrollment if they had any previous or current diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar disorder or dementia. Patients were also excluded from the study if their current depressive episode had persisted for ≥6 months, if they were experiencing treatment-resistant chronic pain or had a painful inflammatory condition related to an identifiable medical condition.

Study design
------------

This prospective, non-interventional, epidemiological, three-month observational study was designed to assess the frequency of PPS occurrence among patients from 6 Asian countries/regions treated in naturalistic clinical settings for an acute episode of MDD. Patients were recruited from 14 June 2006 to 15 February 2007. We now present data from a subanalysis of all Korean patients who completed both baseline and endpoint visits.

Treatment for MDD was prescribed through the usual standard of care by the treating physician, and was not provided or directed by the study sponsor. All subsequent treatment changes were solely at the discretion of the physician and the patient, and there was no attempt by the sponsor to influence prescribing patterns.

Upon joining the study entry, patients were assessed for the presence of PPS as measured by their mean score on the pain related items of the modified Somatic Symptom Inventory (SSI)\[items 27 (joint pain) and 28 (neck pain) were added\].[@B31] Patients with a mean score of ≥2 were defined as painful physical symptom positive (PPS+) and the remaining patients were defined as painful physical symptom negative (PPS-). The SSI items are rated on a scale of 1 to 5; 1 is defined as \"not at all\" and 2 to 5 indicate presence of symptoms in increasing severity.[@B32]

Following enrollment, patients were observed for three months. To collect data during the study, there was a total of two visits, at baseline and study end. Upon entering the study, patients were assessed for eligibility and consent to release information was received from each patient or their legal representative prior to enrolment.

This study was not designed to assess the overall safety profile of any study drug. The study investigators had an obligation to report any spontaneous treatment-emergent adverse events and serious adverse events, just as they would in normal clinical practice.

The study protocol (study code: F1J-AA-B015) was submitted to and subsequently approved by the local regulatory agency as well as each institutional review board. This study was carried out in accordance with the ethical principles that have their origin in the Declaration of Helsinki. These principles are also consistent with good clinical practices in addition to Korean laws and regulations.

Measures
--------

Demographic and clinical data, including disease history, work, hospitalization and medical comorbidities, were collected at baseline. Clinical data was also collected at endpoint. Depression severity was measured using the 17-item Hamilton Depression Rating Scale (HAMD~17~) [@B33] and CGI-S. Response was defined as a ≥50% reduction in HAMD~17~ total score from baseline to endpoint. Remission was defined by a HAMD~17~ total score of ≤7 at endpoint. Pain severity was measured using a Visual Analog Scale (VAS)[@B34] and patient quality of life was assessed using the EuroQol Questionnaire-5 Dimensions (EQ-5D). The EQ-5D is a self-administered questionnaire that provides a utility score related to health state and impact on usual life activities including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A set of weights that represent the general population\'s preferences is employed to create the index.[@B35] For the EQ-5D scale, a United Kingdom population was used to standardize scores as a Korean population has not been validated.

Statistical analysis
--------------------

The primary analytical objective for this study, to estimate the frequency of PPS within the full study cohort, has been previously reported.[@B27] Demographic characteristics and treatment patterns of patients were evaluated across PPS groups using: 1) two-sample t-test or nonparametric Wilcoxon rank sum test for continuous variables, 2) Fisher\'s exact test for categorical variables and 3) analysis of covariance (ANCOVA) for changes from baseline on clinical outcome variables (HAMD~17~, CGI-S, VAS and EQ-5D) adjusted for propensity scores. In this study the propensity score represents the conditional probability of a patient being PPS+ given their baseline data. The propensity score was calculated with a logistic regression model using the following baseline variables defined a priori: gender, age, age at first episode, illness severity, previous depressive episodes (yes/no), number of previous depressive episodes, number of significant pre-existing comorbidities and previous depression treatment (drug and non-drug). In this study, the propensity score represents the conditional probability of a patient being PPS+ given their baseline data. Further interaction terms determined post hoc included CGI-S with EQ-5D, SSI with VAS and EQ-5D with number of significant pre-existing comorbidities.[@B36]

Comparisons between selective serotonin reuptake inhibitor (SSRI) and serotonin and norepinephrine reuptake inhibitor (SNRI) monotherapy groups were evaluated at baseline and for changes from baseline (adjusted for baseline, age and sex). Logistic regression was used to evaluate the number of patients achieving response and remission, with comparisons made between PPS groups (adjusted for propensity scores). All statistical analyses were performed using SAS® Version 8.2 for Windows™ (SAS Institute, Cary, NC). No adjustment for multiple comparisons was performed. The level of statistical significance was defined a priori as alpha=0.05.

Results
=======

Patient disposition
-------------------

A total of 198 patients were enrolled in Korea, of which 46.0% (91/198) were PPS+ and 54.0% (107/198) were PPS-. The overall completion rate in the study was 74.2% (147/198), with 71.4% (65/91) of completers in the PPS+ group and 76.6% (82/107) of completers in the PPS- group. Forty-eight patients were lost to follow-up \[28.6% (26/91) PPS+ patients and 20.6% (22/107) PPS- patients\]. In the PPS- group, two patients voluntarily discontinued and one patient committed suicide during the study. There were no statistically significant between-group differences regarding reasons for discontinuation.

Demographic and disease characteristics at baseline
---------------------------------------------------

The demographic and disease characteristics of PPS+ and PPS- patients at baseline are detailed in [Table 1](#T1){ref-type="table"}. Significantly more patients in both groups were women \[overall: 68.7% (136/198), p=0.009\]. Patients had a mean \[standard deviation (SD)\] age of 49.5 (14.17) years and a mean body mass index (BMI)(SD) of 22.9 (3.05) kg/m^2^. Overall, patients experienced their first depressive episode at the mean age (SD) of 46.5 (14.1) years, 35.9% (66/184) of patients had one or more previous depressive episodes with a mean (SD) episode duration of 11.4 (10.14) weeks. In the PPS+ group, the mean (SD) duration of the current depressive episode was 8.7 (7.83) weeks, while in the PPS- group it was 7.6 (5.84) weeks, but not statistically significant. The most frequently reported medical comorbidities were cardiovascular disease \[PPS+: 15.4% (14/91); PPS-: 16.8% (18/107)\], diabetes mellitus \[PPS+: 8.8% (8/91); PPS-: 6.5% (7/107)\] and gastrointestinal disease \[PPS+: 7.7% (7/91); PPS-: 7.5% (8/107)\].

Depression measures
-------------------

At baseline, PPS+ was associated with significantly greater severity of depression and poorer clinical status than PPS- based on CGI-Severity score \[PPS+ Mean (SD): 5.1 (0.79); PPS-: 4.6 (0.76); p\<0.001\], HAMD~17~ total score \[PPS+ Mean (SD): 24.3 (5.24): PPS-: 20.8 (5.12); p\<0.001\], HAMD anxiety/somatization \[PPS+ Mean (SD): 8.7 (2.44); PPS-: 7.5 (2.90); p=0.006\] and HAMD core mood subscores \[PPS+ Mean (SD): 8.7 (2.96); PPS-: 7.5 (2.45); p=0.007\]([Table 1](#T1){ref-type="table"}). From baseline to endpoint, there was a statistically significant (p\<0.001) improvement in all depression severity measures in both PPS+ and PPS- patients (adjusted mean change from baseline to endpoint) ([Figures 1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}); no significant between-group differences were found. There were no statistically significant differences between groups in terms of the proportion of responders or remitters at endpoint \[difference in response (PPS+ minus PPS-): -0.06, 95% CI (-0.21, 0.10), p=0.487; difference in remission (PPS+ minus PPS-): -0.06, 95% CI (-0.22, 0.10), p=0.506\].

Pain measures
-------------

As expected, PPS+ patients reported significantly greater (p\<0.001) pain severity at baseline than PPS- patients based on the VAS overall and subscales ([Table 1](#T1){ref-type="table"}). At endpoint, patients in both groups experienced a significant improvement in pain severity \[adjusted mean change from baseline; p\<0.001 for PPS+ and PPS- patients on VAS overall and all subscales, except for PPS+ patients with shoulder pain (p=0.008)\], improvement being prominent in the pain interference, pain while awake, and headache subscales ([Figure 3](#F3){ref-type="fig"}). Between-group differences in pain severity measures from baseline to endpoint were not statistically significant ([Figure 3](#F3){ref-type="fig"}).

Quality of life measures
------------------------

At baseline, PPS+ patients had significantly (p\<0.001) lower quality of life \[EQ-5D health state score mean (SD): 39.4 (20.52); EQ-5D utility score mean (SD): 0.2 (0.36)\] than PPS- patients \[EQ-5D health state score mean (SD): 51.3 (20.78); EQ-5D utility score mean (SD): 0.5 (0.30)\]. Both groups of patients had statistically significant improvements in quality of life (p\<0.001) from baseline to endpoint {PPS+ \[adjusted mean change in EQ-5D health state score (95% CI)\]: 20.9 \[16.11, 25.64\]; adjusted mean change in EQ-5D utility score \[95% CI\]: 0.3 \[0.27, 0.40\]}{PPS- \[adjusted mean change in EQ-5D health state score (95% CI)\]: 24.0 \[19.78, 28.22\]; adjusted mean change in EQ-5D utility score \[95% CI\]: 0.4 \[0.36, 0.47\]}.

Work and hospitalization
------------------------

During the three months prior to the study, 74.4% (67/90) of PPS+ patients and 65.1% (69/106) of PPS- patients were unemployed. During the three-month study period, 68.5% (50/73) of PPS+ patients and 67.0% (61/91) of PPS- patients were unemployed. Patients that did work during the study period worked on average a total of 40 hours per week and did not miss a day of work due to MDD (range 0-9 days).

A total of eight patients required psychiatric hospitalization during the study. In the PPS+ group, 7.8% of the patients were hospitalized, whereas 3.8% of the patients in the PPS- group were hospitalized; however, these results were not statistically significant. During the study, 4.7% of PPS+ patients and 1.3% of PPS- patients required 29 days or more of hospitalization.

Treatment patterns
------------------

Of 197 patients reporting treatment at study entry, 53 patients were not receiving any treatment and 144 patients were receiving one or more treatments. There was no statistically significant difference between PPS+ or PPS- patients in terms of medication class, number, and psychosocial therapy. A small proportion of patients \[11.4% (22/193)\] were receiving some treatment for pain at baseline. More PPS+ patients \[12.2% (11/90)\] used one or more classes of concomitant treatment.

The most commonly prescribed antidepressants at baseline and at endpoint were the SSRI paroxetine and escitalopram, followed by mirtazapine and venlafaxine. The most common reason for discontinuation of MDD treatment was inadequate response to treatment, followed by the investigator\'s or patient\'s perception of cure. A total of eight patients discontinued their MDD medication due to an adverse event

There was no statistically significant difference between treatments with SSRI \[at baseline: PPS+ n=39 (42.9%); PPS- n=52 (48.6%)\] versus SNRI \[at baseline: PPS+ n=15 (16.5%); PPS- n=9 (8.4%)\] monotherapy from baseline to endpoint. This was the case in all enrolled patients in terms of depression severity and quality of life as measured by CGI-S, HAMD~17~ total score, HAMD~17~ anxiety/somatization, HAMD~17~ core mood and EQ-5D health state and utility scores. However, both groups of patients did experience statistically significant improvement in depression severity and quality of life with both treatments. Similar results were obtained when comparing both treatments based on the VAS as a pain severity measure. Overall, statistically significant pain relief was experienced by patients receiving both SSRI and SNRI treatments regarding overall pain, headache severity, pain interference and pain while awake.

Discussion
==========

In this Korean subanalysis of a multicountry, three-month, prospective, noninterventional study in Asian patients with MDD,[@B27] the frequency of PPS in the Korean subpopulation was found to be 46.0%. Although clinicians may assume that as a result of greater cultural acceptance, PPS are more frequent in Asians,[@B37],[@B38] the observations in this study do not support this assumption. The frequency of PPS reported in Koreans was comparable to the prevalence found in Europe (43.0%),[@B26] but lower than that reported in the overall Asian study (51.8%),[@B27] and even lower when compared with results reported in North America (69.0%)[@B24] and Latin America (73.0%).[@B25]

PPS reporting is usually linked to reporting and interpretational bias, can be culturally sensitive and also reflects country-specific training practices of health care professionals, for instance, how complaints are explored. Country-specific data and subanalyses can, therefore, help to reveal such country-specific differences, while cross cultural studies can indicate potential linkages between cultural values, socialization practices and symptom reporting.[@B39],[@B40] Additionally, the study was conducted in university hospitals in Korea, which exist as tertiary referral centers. As a result, patients treated in major university hospitals cannot be said to be representative of the MDD population in Korea. Although this study was carried out in patients presented to psychiatrists in the cultural ambience of Korea, patients with MDD and PPS may be more likely to present to other specialties with complaints of pain as opposed to psychiatrists with depression.

In Korean patients with acute MDD, the presence of PPS at baseline was associated with a greater severity of depression and poorer quality of life. Similar outcomes were observed for the overall study and other evaluated Asian subpopulations evaluated.[@B27] By study end, both PPS+ and PPS- patients had improved significantly in terms of their depression and quality of life. There was a trend towards more severe depression and poorer quality of life for PPS+ patients compared to the overall study sample. However, no statistically significant difference in terms of depression and quality of life between PPS+ and PPS- patients was observed by study end.

As the Korean patient sample was predominantly comprised of women who had experienced their first depressive episode later in life (46.5 years of age on average) than commonly expected,[@B41] it is possible that these patients were going through perimenopausal or menopausal depression, which is commonly related to PPS.[@B42] Also of note was the high rate of unemployment observed in both PPS+ and PPS- patients in the three months prior to the study commencement and during the study period in this Korean sample. However, the assessment did not differentiate between unemployment and women working full time as housewives, who were also classified as unemployed. Following the financial crisis in 1997, Korean workers no longer enjoyed lifetime employment that had previously characterized the work environment in this country.[@B43] Instead, Korean companies have enforced early retirement, honorary retirement and layoffs to reduce their payrolls.[@B43] In 2003, Jang reported that only 60.0% of Korean workers in their early thirties will still be employed by the time they become 50 years old.[@B44]

In terms of treatment, a previous study has verified the utility of SNRIs (duloxetine) as efficacious and safe treatments for emotional and physical symptoms of MDD in a predominantly Asian patient sample.[@B45] In the Korean subpopulation, no statistically significant between-group difference in treatments were found with SSRIs and SNRIs. While there were no statistical differences between PPS+ and PPS-, the PPS+ group did show a trend to fare less well in their treatment. The PPS+ group experienced lower completion rates, higher hospitalization rates with more stays over 29 days, more required classes of treatment, and less improvement in all efficacy measures. Antidepressant selection patterns based on psychiatric symptoms with and without PPS were not considered in the statistical comparison, but might be undertaken in further analyses.

Depressive symptoms in Korean people can be perceived in a complex way, intricately overlapping in all domains of a person\'s existence.[@B46] DSM-IV currently lists hwa-byung as a Korean culture-bound syndrome typically associated with middle-aged and elderly women that results from distressed emotions and passive suffering. It is related specifically to the Korean way of perceiving and reacting to intolerable situations.[@B15] Furthermore, it is characterized by predominantly physical symptoms of depression and anhedonia, generally lacking subjective awareness of depressed feelings. This is comparable to Kohut\'s concept, where affective disorders result from extreme fear, threat to self-esteem or worth and the shame of being faced with failure (narcissistic rage).[@B47] Similarly, McDougall associated the presence of somatic symptoms in alexithymic patients with a response or defense mechanism against frightening experiences.[@B48]

Just as depression has a complex biopsychosocial etiopathogenesis, perception of pain is also a complex phenomenon. The subjective experience of pain results from central integration of painful stimuli, along with emotional and cognitive factors. It is suggested that depression may contribute to increased excitability of the central nociceptive pathways via the limbic system input,[@B49],[@B50] and ultimately contribute to pain sensation. Chronic pain may also contribute to depression. In chronic pain, the somatosensory pathway is not activated, but rather the depression pathway, with signals from the limbic system. The kindling model has been applied to pain-induced neuroplastic changes and corticolimbic sensitization, leading to a clinical picture of persistent pain, affective dysregulation and disturbances in behavior.[@B51]

Along with the stigma of mental illness, Koreans in general tend to have a greater acceptance of physical rather than mental pain. In this context, it can be speculated that the frequency of PPS may be higher in Korean patients with MDD; however, this study cannot confirm or refute this hypothesis.

Results from the overall multicountry study revealed that PPS are experienced by approximately half of patients with MDD in Asia and are associated with poor clinical status and less pain reduction.[@B27] The greater adjusted pain reduction experienced by PPS- patients may indicate that depression with substantial pain requires a different treatment strategy. This strategy would differ from SSRI treatment, which is what the majority of patients received. On the other hand, another possible explanation for less pain reduction in the presence of somatic symptoms is Freud\'s concept of guilt, which sustains that self-flagellation, reflected in this case as the presence of somatic symptoms, is an expression of the patient\'s resistance to recovery.[@B45]

Limitations
-----------

It is important to note that the overall study of 6 Asian countries/regions may not be powered for country-specific analyses, and therefore, data should be interpreted with caution. Patients without postbaseline visits and measures for all covariates were excluded from the analysis, resulting in a reduced size of the country-specific analysis population. The findings presented for this Korean subpopulation are for descriptive and explorative purposes and must be interpreted within these confines.

Even though the gender findings were consistent with that of the overall study across all Asian cohorts (68.7% to 78.0% of patients were women who presented PPS with an overall onset of first depressive episode at 41.0 years of age),[@B27] these elements could be potential confounders. The high unemployment rates observed in this Korean population may be more related to the Korean employment pattern or the higher percentage of unemployed housewives, than the severity of their depression. This could be another confounder. Additionally, the validity of the pain scores used may not be well established and suitably devised for all ages and genders.

Conclusions
-----------

In this study, almost half of the Korean MDD patients experienced PPS. As PPS has been associated with more severe depression, lower quality of life and a trend towards poorer outcomes, clinical management should aim to address associated mental and physical symptoms. Our results support previous findings in Asia, indicating that the presence of PPS is associated with more severe depression.[@B27] Overall, despite the established appreciation of pain perception complexities, further research is needed to explore the impact of such complexities on choices of effective treatment modalities.
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![Adjusted mean change from baseline to endpoint in HAMD~17~ total score, anxiety/somatization and core mood. ^a^p-values for adjusted mean differences \[HAMD~17~ total score=0.41, 95% CI (-1.69, 2.51); Anxiety/somatization subscore=0.28, 95% CI (-0.59, 1.16); Core mood subscore=0.36, 95% CI (-0.47, 1.19)\] using Type III Sums Of Squares from analysis of covariance (ANCOVA) model: change=PPS group, propensity score and baseline. ^\*^Within group p-value (p\<0.001) from ANCOVA model: change=PPS group, propensity score and baseline, and is the same for HAMD~17~ total score and both subscores that are presented here. PPS+: painful physical symptom positive group, PPS-: remainder of study population, HAMD~17~: 17-item Hamilton Depression Rating Scale, CI: confidence interval.](pi-6-255-g002){#F2}
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^\*^p-value using t-test for comparison of means, ^\*\*^p-value using non-parametric Wilcoxon Rank Sum Test, ^\*\*\*^p-value using Fisher\'s Exact Test. PPS+: painful physical symptom positive group, PPS-: remainder of study population, n: number of patients in each group, N: number of patients in the total study population, SD: standard deviation, MDD: major depressive disorder, CGI-Severity: Clinical Global Impressions of Severity Scale, HAMD17: 17-item Hamilton Depression Rating Scale, VAS: Visual Analog Scale, EQ-5D: EuroQol Questionnaire-5 Dimensions
